Merck & Co., Inc. Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)
Merck & Co., Inc. (MRK) had Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) of $6.00 million as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Derivative Instruments and Hedging Activities › Summary of Derivative Instruments › Discontinuation of Fair Value Hedge Accounting
us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease · last filed 2018-11-06
- 2018-09-30: Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) $6.00M.
- 2018-06-30: Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) $7.00M.
- 2017-12-31: Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) $11.00M.
| Period end | Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) |
|---|---|
| 2018-09-30 | $6.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $7.00M 10-Q · filed 2018-08-07 |
| 2017-12-31 | $11.00M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |